Biotech Stock News (SYN) (CNAT)

Synthetic Biologics (NASDAQ:SYN) On February 3, 2016 shares of Synthetic Biologics fell by 14% after the company announced an update on the phase 2 clinical trial treating patients with Relapsing-Remitting Multiple Sclerosis — RRMS. The company’s drug used to treat these patients with RRMS is known as Trimesta. Both the clinical and MRI results of … Read more